PeptideFactSheetsAn independent reference
Menu

Glutamatergic research small molecule · Fact sheet

Fasoracetam

Also known as NFC-1 · NS-105

Fasoracetam was studied in adolescents with ADHD and selected glutamate-network genetic variants. An exploratory short study cannot establish a general ADHD treatment or a cognitive-enhancement regimen.

Not FDA approvedEarly human evidence
Brain, mood & sleep

What is Fasoracetam?

Fasoracetam is associated with metabotropic glutamate signaling research. It is not an approved ADHD medicine.

A genetically selected adolescent population is narrower than ADHD in general.

Benefits & claims

Readers encounter Fasoracetam in discussions of cognition, mood or mental fatigue. The relevant study population and outcome determine whether those claims are supported.

What the evidence supports

  • Clinical rating scores improved during the five-week study.
  • Without a conventional parallel randomized placebo group throughout treatment, improvement cannot be attributed confidently to the drug.
  • The findings do not establish efficacy across all ADHD populations or in healthy adults.
Research areas
  • Cognition and memory
  • Neurologic or psychiatric research

Dosage & frequency

Human study context

The original human study supplies an exposure reference, not an established cognitive-enhancement regimen.

NFC-1 adolescent exploratory study

30 adolescents aged 12–17 with ADHD and selected mGluR-network variants

Amount
Symptom-driven escalation up to 400 mg twice daily
Frequency
Placebo at week 1, followed by four weeks of active-dose advancement
Route studied or labeled
Oral

The amount is the protocol ceiling, not a starting amount. Single-dose pharmacokinetic testing was a separate component. Full escalation and monitoring rules are omitted; no routine adolescent regimen is established.

Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.
How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A genetically selected adolescent population is narrower than ADHD in general.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations
Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Fasoracetam study NCT02286817 A Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical.

Side effects & risks

  • No adverse-event incidence difference was found between the placebo week and active weeks, but the sample and duration were small.
  • Pediatric chronic safety, interactions and broader psychiatric effects remain uncertain.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

The 30-person study used a placebo week followed by symptom-driven active treatment. Its open-label and single-blind features limit causal interpretation.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

Fasoracetam is not an FDA-approved treatment for the cognitive or mood uses discussed here. Regional use, historical trials and online availability are separate from U.S. drug approval.

Early human research; no FDA approval

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Reproducible benefit on everyday function in the intended population
  • Long-term safety and clinically important interactions
  • Equivalence of nonstandard products to research formulations

Summary

The findings do not establish efficacy across all ADHD populations or in healthy adults.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedFasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling.

    30 adolescents with selected network variants; exploratory five-week design.

  2. clinical trialsFasoracetam study NCT02286817

    Official record for the selected adolescent ADHD study.

  3. pubmedA Study of Fasoracetam's Solid State Forms: A Potential Anti-Alzheimer Pharmaceutical.

    Solid-state formulation investigation, not a human efficacy study.

How we assess sources · Suggest a correction